Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice

✍ Scribed by Donatella Dondi; Roberta M. Moretti; Marina Montagnani Marelli; Graziella Pratesi; Donatella Polizzi; Mario Milani; Marcella Motta; Patrizia Limonta

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: French
• Weight: 131 KB
• Volume: 76
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/(sici)1097-0215(19980518)76:4<506::aid-ijc11>3.0.co;2-5

✦ Synopsis

Experiments have been performed to clarify whether LHRH agonists might decrease growth of hormone-unresponsive prostate cancer in vivo. Male nude mice were injected s.c. with the human androgen-independent prostate tumor DU 145 cells; osmotic minipumps releasing the LHRH agonist Zoladex (LHRH-A) for 14 days were simultaneously implanted under the skin. Treatment with LHRH-A induced a significant decrease in tumor growth up to the end of the treatment. In subsequent experiment, minipumps releasing LHRH-A were implanted in nude mice either 7 or 14 days after cell inoculation. When the treatment was started 7 days after inoculation of the cells, tumor growth was significantly decreased up to 28 days; thereafter, tumor volume remained lower than in controls, although not significantly. When LHRH-A was administered beginning 14 days after cell inoculation, tumor growth was not significantly affected at any time interval considered. LHRH-A did not appear to induce apoptosis in DU 145 cells, at least on the basis of the apoptotic index and immunohistochemical staining of the p53 protein. On the other hand, treatment with LHRH-A was accompanied by a significant decrease of the concentration of epidermal growth factor receptors in DU 145 prostate cancer specimens. Our results show that the LHRH agonist used significantly inhibits the growth of DU 145 androgenindependent prostate tumor xenografts in nude mice. Int.